Navigation Links
XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
Date:10/22/2007

be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing of its regulatory filings, the timing of the commercialization of its products and the timing of the initiation of its U.S. pivotal trial. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's most recent quarterly report on Form 10-Q for the quarter ended June 30, 2007. This quarterly report was filed with the SEC on August 13, 2007, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Information about XTENT is available at our website at http://www.xtentinc.com.


'/>"/>
SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... YORK , Oct. 22, 2014 Sanomedics ... August 2014 report by Global Research & Data Services, ... per year from 2014 through 2018, as demand for ... States is the world,s largest market for ... with advanced thermometers is Sanomedics International Holdings, Inc. ...
(Date:10/22/2014)... REDWOOD CITY, Calif. , Oct. 22, 2014 ... ) today announced that results from the  IAP310 ... and Pain Medicine (RAPM), a peer-reviewed journal ... placebo-controlled, Phase 3 trial evaluating the safety and ... sufentanil sublingual tablet system (SSTS), for the treatment ...
(Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( ... pulmonology, today announced completion of enrollment in their RENEW ... Clinical Study is the FDA-approved IDE pivotal trial for ... emphysema. It was anticipated that the study, ... 2013, would take until the end of 2014 to ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... SuperGen Inc.,(Nasdaq: SUPG ), a pharmaceutical company ... therapies for solid tumors and,hematological malignancies, today announced ... poster presentations at the AACR Annual Meeting,which will ... An oral presentation by Dr. Steven Warner ...
... A biosimilar product for,treating the negative effects ... cells of patients is safe and exhibits an ... This is the result of a clinical phase ... Pharma GmbH and the Indian manufacturer,INTAS Biopharmaceuticals Ltd. ...
Cached Medicine Technology:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting 2SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting 3Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 2Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 3
(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... 2014 Hay House is pleased to announce ... Upgrade Your Life (Paperback; $10.82) written by the highly esteemed ... This book is meant to help readers of all ... recovery. , Recovery 2.0 is not the average self-help ... is a guide for what comes next. For ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... Although there are only 24 hours in a ... who have trouble finding time within their busy schedules for exercise ... periods of time to get in shape. Here are five ways ... go. , Change Up Your Commute , Consider riding a ... some exercise into your daily routine. If you must use your ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
... and Erosive ... Esophagitis, OSAKA, Japan, Oct. ... and,Development Center, Inc., a wholly owned United States (U.S.) subsidiary,received notification from ... able to complete its review of the TAK-390MR New,Drug Application (NDA) by ...
... Pulse Report Released Today, SOUTH BEND, Ind., ... report released today confirms patients have heightened expectations,of ... to choose where,they receive care. Health care facilities ... experience to maintain and improve patient retention,rates. The ...
... achievement, a feature story on Mary Hall will appear on ... ... 18, 2008 -- Mary Hall, CEO of iHealthspot, Inc. a leading ... membership into Fort Lauderdale City Limits "Profiles of Excellence" in the ...
... to Care in Underserved,Communities, SAN DIEGO, Oct. ... care to underserved residents of San Diego County,La ... the,expansion of its telemedicine program, thanks to a ... used to purchase new equipment including a camera,that ...
... TB, fight other drug-resistant bacteria , , FRIDAY, Oct. 17 ... perfecting a new class of broad-spectrum antibiotics that could ... , The new antibiotics compounds -- all of which ... other bacteria -- also show promise as a more ...
... Oct. 17 /PRNewswire-FirstCall/ - The Westaim Corporation,announced ... its wholly owned,subsidiary iFire Technology Ltd. and ... sell its equipment, patents and intellectual property,for ... sale is subject to,several conditions, including iFire ...
Cached Medicine News:Health News:FDA Adds Three Months to Review of Takeda's New Drug Application for TAK-390MR 2Health News:Report Confirms Consumer Selection is a Driving Force in Health Care Today 2Health News:Report Confirms Consumer Selection is a Driving Force in Health Care Today 3Health News:Mary Hall, CEO of iHealthSpot, Inc., is Awarded Membership Into Fort Lauderdale City Limits "Profiles of Excellence" 2Health News:La Maestra Community Health Centers Expands Telemedicine Program 2Health News:La Maestra Community Health Centers Expands Telemedicine Program 3Health News:Scientists Hot on Trail of New Antibiotics 2Health News:Westaim announces sale of iFire Technology Ltd. assets 2
... The Sphincter of Oddi ... (PNET) works with the Polygraf™ ... and analyze pressure signals from ... The PNET software and Polygraf ...
... VoiceControl is a unique tool ... voice commands to activate shortcut ... eliminating the need to perform ... you can devote your full ...
... Analysis for POLYGRAM NET™ works with the ... analyze multichannel EGG signals. The EGG analysis ... by performing an automatic electrode impedance check ... beginning of a recording. If the electrode ...
... POLYGRAM NET™ (PNET) works with the ... analyze pressure and EMG signals from ... graphic format. The PNET software and ... or water-perfused manometry catheters as well ...
Medicine Products: